

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. As single agents, PARP inhibitors have shown activity in \_\_\_\_\_.
  - a. BRCA1 mutation-positive ovarian cancer (OC)
  - b. BRCA2 mutation-positive OC
  - c. BRCA germline-normal OC
  - d. Both a and b
  - e. All of the above
2. The FDA recently approved olaparib monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated advanced OC previously treated with 3 or more lines of chemotherapy.
  - a. True
  - b. False
3. Studies investigating anti-PD-1/PD-L1 antibodies have shown these agents to produce response rates of approximately \_\_\_\_\_ for patients with relapsed/refractory OC.
  - a. <5%
  - b. 20%
  - c. 40%
  - d. 80%
4. Both the GOG-0218 and ICON7 trials demonstrated an improvement in progression-free survival with the addition of bevacizumab to adjuvant chemotherapy for patients with newly diagnosed OC.
  - a. True
  - b. False
5. Bevacizumab is FDA approved for which of the following gynecologic cancers?
  - a. Platinum-resistant recurrent epithelial OC
  - b. Persistent, recurrent or metastatic cervical cancer
  - c. Platinum-sensitive recurrent epithelial OC
  - d. Both a and b
  - e. Neither a nor b
6. NCCN guidelines recommend that \_\_\_\_\_ undergo BRCA testing.
  - a. All patients with epithelial OC
  - b. Only patients with an Ashkenazi Jewish background
  - c. Only patients with a strong family history of breast or ovarian cancer at a young age
7. Mirvetuximab soravtansine (IMGN853) is \_\_\_\_\_.
  - a. An anti-angiogenic agent
  - b. An antibody-drug conjugate
  - c. A PARP inhibitor
8. Which of the following toxicities has been observed with mirvetuximab soravtansine?
  - a. Alopecia
  - b. Blurred vision
  - c. Peripheral neuropathy
  - d. All of the above
9. WEE1 is \_\_\_\_\_.
  - a. An antibody-drug conjugate
  - b. A PARP inhibitor
  - c. A tyrosine kinase inhibitor
10. Ongoing studies of WEE1 in combination with chemotherapy have reported responses in which of the following patient populations?
  - a. Patients with platinum-sensitive OC
  - b. Patients with platinum-resistant OC
  - c. Both a and b
  - d. Neither a nor b